Drugmaker stocks were on the move Monday as the American Society of Clinical Oncology (ASCO) meeting continued to produce key data on cancer trials. Among the top movers were: ImmunoGen (IMGN) stock soared as much as 71% to a 13-month high above 15 based on its Saturday report on its phase-one trial of mirvetuximab soravtansine, or IMGN853, in ovarian cancer. The objective response rate — the percentage of tumors that shrank — was 53%, which
Sina (SINA) stock rose to an eight-month high Monday as the company announced that its CEO would buy 11 million newly issued ordinary shares of Sina stock, apparently showing confidence in the Shanghai-based Web portal as expectations of more government stimulus programs continue to buoy China’s economy. Sina CEO Charles Chao will pay $456 million or $41.49 per share for Sina stock, the company said, and Chao will subscribe for and purchase
F5 Networks (FFIV) stock might be range-bound until revenue growth reaccelerates, says Citigroup, which on Monday downgraded the stock to neutral but raised its price target. Citigroup analyst Ehud Gelblum hikes his price target to 132 from 122. F5 Networks stock, which has slipped 5% this year, was down 1% in morning in the stock market today, near 124.50. Seattle-based F5 Networks is the No. 1 seller of application delivery controllers, which